EUCTR2019-004497-25-FI进行中（未招募）1 期
Interventional, randomized, double-blind, parallel-group, placebo-controlled study with an extension period to evaluate the efficacy and safety of eptinezumab for the prevention of migraine in patients with unsuccessful prior preventive treatments
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 840
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The patient has a diagnosis of migraine, with a history of chronic or episodic migraines of at least 12 months prior to the Screening Visit
- •The patient has a migraine onset of =50 years of age.
- •The patient has =4 migraine days per month for each month within the past 3 months prior to the Screening Visit.
- •The patient has demonstrated compliance with the Headache eDiary by entry of data for at least 24 of the 28 days following the Screening visit prior to randomization
- •The patient fulfils the following criteria for chronic migraine (CM) or episodic migraine (EM) in prospectively collected information in the eDiary during the screening period:
- •For patients with CM: Migraine occurring on =8 days and headache occurring on >14 days
- •For patients with EM: Migraine occurring on =4 days and headache occurring on =14 days
- •The patient has documented evidence of treatment failure (must be supported by medical record or by physician’s confirmation specific to each treatment) in the past 10 years of 2-4 different migraine preventive medications.
- •The patient has a history of either previous or active use of triptans for migraine.
- •Other inclusion criteria may apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 715
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 125
排除标准
- •The patient has experienced failure on a previous treatment targeting the calcitonin gene-related peptide (CGRP) pathway.
- •The patient has a treatment failure on valproate/divalproex or botulinum toxin A/B and the treatment is not the latest preventive medication prior to study inclusion. The medication is regarded as the latest if the medication start date is after the start date of the other preventive medications and the medication stop date is after the stop date of the other preventive medications.
- •The patient has confounding and clinically significant pain syndromes, (e.g., fibromyalgia, chronic low back pain, complex regional pain syndrome).
- •The patient has a diagnosis of acute or active temporomandibular disorder.
- •The patient has a history or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), ophthalmoplegic migraine, and migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration).
- •The patient has a psychiatric condition that is uncontrolled and/or untreated for a minimum of 6 months prior to the Screening Visit. Patients with a lifetime history of psychosis and/or mania in the last 5 years prior to the Screening Visit are excluded.
- •The patient has a history of clinically significant cardiovascular disease or vascular ischaemia or thromboembolic events (e.g., cerebrovascular accident, deep vein thrombosis, or pulmonary embolism).
- •Other exclusion criteria may apply
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of eptinezumab in patients with episodic cluster headacheEpisodic cluster headacheMedDRA version: 24.0Level: PTClassification code 10059133Term: Cluster headacheSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-001969-37-DKH. Lundbeck A/S304
进行中（未招募）
1 期
A Study of Eptinezumab in Participants With Migraine and Medication Overuse HeadacheMigraine and medication overuse headacheMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10072720Term: Medication overuse headacheSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-003049-40-NOH. Lundbeck A/S570
进行中（未招募）
1 期
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophreniaschizophrenia with persistent prominent negative symptomsMedDRA version: 20.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2018-001581-42-LVH. Lunbeck A/S240
已完成
3 期
Eptinezumab in Participants With Episodic Cluster HeadacheJPRN-jRCT2041210133Masanari Yazawa231
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of eptinezumab in patients with episodic cluster headacheEpisodic cluster headacheMedDRA version: 24.0Level: PTClassification code 10059133Term: Cluster headacheSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-001969-37-DEH. Lundbeck A/S304